All AbMole products are for research use only, cannot be used for human consumption.
In vitro: Brivaracetam in vitro exerts a dose-dependent cytotoxic effect on various glioma cell lines and this effect is concomitant with the modulation of a number of miRNAs.
In vivo: Brivaracetam reduces spike-wave discharges in Alzheimer's disease mice and reverses impairments in spatial memory in APP/PS1 mice. Human pharmacology studies have shown that brivaracetam has a half-life of approximately 8 h and does not vary with the administered dose. It has nearly complete bioavailability. Plasma protein binding is weak (20%), the volume of distribution, 0.6 l/kg, being close to that of total body water. Brivaracetam is primarily metabolized via hydrolysis of the acetamide group and CYP2C8-mediated hydroxylation. Its metabolites are not pharmacologically active. Brivaracetam is neither mutagenic nor clastogenic. Single oral doses of brivaracetam, up to 1000 mg and repeated oral doses up to 800 mg/d b.i.d., are well-tolerated in healthy volunteers and in patients. Treatment-emergent adverse events are mostly CNS-related and transient, and their intensity is usually mild or moderate. Repeated intake of the drug reduces their incidence.
| Cell Experiment | |
|---|---|
| Cell lines | U87MG cell line, SW1783 and T98G cells |
| Preparation method | Cytotoxicity of BRV was studied by cell proliferation assay. |
| Concentrations | 0-2500 μM |
| Incubation time | 0-24-48-72 h |
| Animal Experiment | |
|---|---|
| Animal models | Transgenic Alzheimer’s disease (AD) mice |
| Formulation | normal saline |
| Dosages | 10 mg/kg |
| Administration | i.p. |
| Molecular Weight | 212.29 |
| Formula | C11H20N2O2 |
| CAS Number | 357336-20-0 |
| Solubility (25°C) | 10 mM in DMSO |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
[3] Philipp von Rosenstiel. Neurotherapeutics. Brivaracetam (UCB 34714)
| Related Sodium Channel Products |
|---|
| Riluzole
Rilutek is a sodium channel protein inhibitor and a new mental compound, which has anticonvulsant, hypnotic, antianxiety, antiischemia and anesthesia properties. Riluzole belongs to the family of use-dependent Na+ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM. |
| A-803467
A-803467 is a potent and selective Nav1.8 sodium channel blocker that potently blocks tetrodotoxin-resistant currents (IC50 = 140 nM). |
| Oxcarbazepine
Oxcarbazepine is an anticonvulsant and mood-stabilizing compound. |
| Ambroxol hydrochloride
AmbroxolHCl is a potent inhibitor of the neuronal Na+ channels, inhibits TTX-resistant Na+ currents with IC50 of 35.2 μM and 22.5 μM for tonic and phasic block, inhibits TTX-sensitive Na+ currents with IC50 of 100 μM. |
| Camostat mesylate
Camostat mesylate is a trypsin-like protease inhibitor, inhibits airway epithelial sodium channel (ENaC) function with IC50 of 50 nM, less potent to trpsin, prostasin and matriptase. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
